Научное досье по ФК азилсартан+хлорталидон Часть 5

Научное досье по ФК азилсартан+хлорталидон Часть 1

Научное досье по ФК азилсартан+хлорталидон Часть 2

Научное досье по ФК азилсартан+хлорталидон Часть 3

Научное досье по ФК азилсартан+хлорталидон Часть 4

Научное досье по ФК азилсартан+хлорталидон Часть 6

Сидорова Людмила Леонидовна — кандидат медицинских наук, доцент, начальник научно-методического отдела Главного военно-медицинского клинического центра «Главный военный клинический госпиталь»

Литература

1. Беленков Ю.Н., Мареев Ю.В. Сердечно-сосудистый континуум// Журнал Сердечная недостаточность.- 2002. – № 1. – с. 7-11.
2. Бубнова М.Г.Современные подходы к лечению и длительному контролю артериальной гипертонии в клинической практике. Фармакологические и клинические особенности блокаторов рецепторов ангиотензина II: фокус на азилсартана медоксомил. Часть 1 №02 2015- с. 69-80
3. Золотовская И.А., Давыдкин И.Л., Тучкова О.В. Возможности лечения артериальной гипертензии у пациентов с фибрилляцией предсердий, перенесших кардиоэмболический инсульт. Кардиологический вестник / №2 / 2016. 62-67
4. Клиническая фармакология.: учебник для вузов / Под ред. В.Г. Кукеса.- 4-е издание., перераб. и доп., - 2009. - 1056 с.
5. Кобалава Ж.Д. Современные проблемы артериальной гипертензии. Блокаторы рецепторов ангиотензина П: достижения и перспективы//http: www.cardiosite.ru/article.asp?id= 1381.
6. Кобалава Ж.Д., Котовская Ю.В., Рубанов А.А. Органопротективные свойства фиксированной комбинации верапамила СР и трандолаприла / Артериальная гипертензия. — 2007. - №4. — с. 266-274.
7. Кобалава Ж.Д., Слизкова Л.А., Тарапата Н.П. Обоснование, опыт и перспективы применения кандесартана цилекситила// Клин.фармакология и терапия. – 2002. - №11. – с. 92-96.
8. Мареев В.Ю., Скворцов А.А., Челмакина с.М., Балтаева Р.У., Беликов Ю.Н. Способны ли ингибиторы ангиотензинпревращающего фермента эффективно контролировать активность ренин–ангиотензин–альдостероновой системы при длительном лечении хронической сердечной недостаточности? // Кардиология. - 1999. – Т. 39, №2 – С. 27-34.
9. Моиссев В.С., Кобалава Ж.Д. Комбинированная фармакотерапия артериальной гипертензии//Серце: журнал для практикующих врачей. — 2002. - №5. — с. 228- 231.
10. Наказ МОЗ України №384 від 24.05.2012 «Уніфікований клінічний протокол первинної, екстреної та вторинної (спеціалізованої) медичної допомоги. Артеріальна гіпертензія»
11. Небиеридзе Д.В. Место блокаторов ангиотензина П в терапии артериальной гипертензии/medinfa.ru/article/16/115785.
12. Органопротекторные свойства кандесарана / Метод.рекомендации. Л.А.Лапшина, Л.Ю.Титова. – Харьков, 2006. – 32с.
13. Петросов С.Л., Фомин В.В. Опыт применения азилсартана медоксомила (Эдарби) у пациентов с артериальной гипертензией в амбулаторной практике. Фарматека, №9, 2015
14. Преображенский Д. В.,. Сидоренко Б. А, Шатунова И. М., Стеценко Т. М., Скавронская Т. В. Тиазидные и тиазидоподобные диуретики как краеугольный камень современной антигипертензивной терапии/ Российский кардиологический журнал. – 2004. -№4.
15. 2013 ESH/ESC Guidelines for the management of arterial hypertension Th e Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) European Heart Journal (2013) 34, 2159–2219
16. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2014;311(5):507-520.
17. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. / Eur. Heart J. - 2016. – Vol. 37. – P. 2119-2200.
18. Abdelsaid Mohammed, Coucha Maha, Ergul Adviye. Cerebrovasculoprotective Eff ects of Azilsartan Medoxomil in Diabetes. Transl Res. 2014 November ; 164(5): 424–432. doi:10.1016/j.trsl.2014.06.003.
19. Adachi S, Miura S, Shiga Y, Arimura T, Kuwano T, Kitajima K, Ike A, Sugihara M, Iwata A, Nishikawa H, Morito N, Saku K.Depressor and Anti-Infl ammatory Eff ects of Angiotensin II Receptor Blockers in Metabolic and/or Hypertensive Patients With Coronary Artery Disease: A Randomized, Prospective Study (DIAMOND Study). J Clin Med Res. 2016 Oct;8(10):743-8.
20. Aliskiren (Rasilez): risk of cardiovascular and renal adverse reactions—new contraindications and warnings Article citation: Drug Safety Update March 2012, vol 5 issue 9: A1. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON146526.
21. Angeloni E. Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy. Core Evidence 2016:11 1–10.
22. Antunes de Araujo A., Varela H., Xavier de Medeiros C.АC et al. Azilsartan Reduced TNF-a and IL-1b Levels, Increased IL-10 Levels and Upregulated VEGF, FGF, KGF, and TGF-a in an Oral Mucositis Model PLoS One. 2015; 10(2): e0116799. Published online 2015, Feb 17. doi: 10.1371/journal.pone.0116799 PMCID: PMC4331549.
23. Antza C., Doundoulakis I., Stabouli S., Kotsis V. Azilsartan, a promising Angiotensin II Receptor Blocker in the management of hypertension Hellenic Atherosclerosis Society2016 VOL. 7 .
24. Bakris GL, Sica D, Weber M et al. The comparative eff ects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13 (2): 81–8.
25. Bakris GL, Sica D, White WB et al. Antihypertensive effi cacy of hydrochlorodiaside vs chlorothalidone combined with azilsartan medoxomil. Am J Med. 2012;125:1229e1-1229e10.
26. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood Press Control 2014; 7: 35–47.
27. Barzilay J.I., Davis B.R., Cutler J.A. et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 diff erent classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Arch. Intern. Med. 2006; 166: 2191-201.
28. Bengtsson C., Johnsson G., Sannerstedt R., Werkö L. Eff ect of diff erent doses of chlorthalidone on blood pressure, serum potassium, and serum urate // Br. Med. J. 1975; 1: 197-9.
29. Black H.R., Davis B., Barzilay J. et al. Metabolic and clinical outcomes in non-diabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Diabetes Care. 2008; 31: 353-60.
30. Bonner G, Bakris G, Sica D et al. Antihypertensive effi cacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27: 479–86.
31. Brown N.J. Aldosterone and end–organ damage // Curr. Opin. Nephrol. Hypertens. – 2005. – Vol. 14(3). – P. 235–241.
32. Calder JA, Schachter M, Sever PS. Potassium channel opening properties of thiazide diuretics in isolated guinea pig resistance arteries. J Cardiovasc Pharmacol. 1994;24:158–64.
33. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4–9.
34. Center for Drug Evaluation and Research [website on the Internet]. Silver Spring, MD: NDA 200-796: Azilsartan medoxomil, Clinical Pharmacology and Biopharmaceutics Review(s) 2010.[Accessed1April,2012]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda /2011/200796Orig1s000ClinPharmR.pdf.
35. Cernes R, Mashavi M, Zimlichman R. Diff erential clinical profi le of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag 2011; 7: 749–59.
36. Chen Peng, Chaugai Sandip, Zhao Fujie, Wang Dao Wen. Cardioprotective Eff ect of Th iazide-Like Diuretics: A Meta-Analysis American Journal of Hypertension 28(12) December 2015.1453-64.
37. Cheng J.W.M. Azilsartan/chlortalidon Azilsartan/chlorotalidon combination therapy for blood pressure control // Integrated blood pressure control 2013:6: 39-48.
38. Cirillo M, Marcarelli F, Mele AA, Romano M, Lombardi C, Bilancio G. Parallel-group 8-week study on chlorthalidone eff ects in hypertensives with low kidney function. Hypertension.2014;63:692-697
39. Collier D, Agabiti-Rosei E, Huang P et al. Combined Azilsartan-medoxomil + chlortalidon is more eff ective at lowering clinic and ambulatory blood pressure than AZK-m monotherapy in incontrolled hypertension patients. European meeting on Hypertension and Cardiovascular protection. June 14017, 2013, Milan, Italy, Oral presentation.
40. Corrao G., Parodi А., Zambon А., Heiman F., Filippi А., Cricelli C., Merlino L., Mancia G. Reduced discontinuation of antihypertensive treatment by two-drug combination as fi rst step. Evidence from daily life practice // J. Hypertens. 2010; 28: 1584-1590.
41. Cushman W.C., Davis B.R., Pressel S.L. et al. Mortality and morbidity during and aft er the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial // J. Clin. Hypertens (Greenwich). 2012. Vol.14. P. 20–31.
42. Cushman WC et al. Azilsartan medoxomil +chlorthalidone reduces blood pressure more eff ectively then olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension Hypertension 2012; 60:310-8.
43. Cushman WC, Sica D, Bakris GL et al. Effi cacy of the azilsartan medoxomil/chlorthalidone fi xed-dose combination by baseline hypertension severity in tree compared-controlled trials. Presented at: Am. Society of Hypertension Annual Scientifi c Meeting. May 15-18, 2013. San Francisco, CA. Poster po-1.
44. Dieter W., Wagner J., Faigle J.W. Binding of chlorthalidone (Hygroton) to blood components in man // Eur. J. Clin. Pharmacol. 1976; 10: 37-42.
45. Dorsch MP, Gillespie BW, Erickson SR at al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
46. Dzau V.J. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Bas Res Cardiol 1993; 88: 1–14.
47. Ellis M., Patterson J. A new class of antihypertensive therapy: angiotensin II receptor antagonists// Pharmacotherapy. – 1996. - vol. 16. – p. 849-860.
48. Erdmann E., G. Riecker "Chronic Heart Failure" Springer-Verland, 1998, 1-272.
49. Ernst M.E., Carter B.L., Goerdt C.J. et al. Comparative antihypertensive eff ects of hydrochlorothiazide and chlorthalidone on ambulatory and offi ce blood pressure // Hypertension. 2006; 47: 352-8.
50. Ernst M.E., Neaton J.D., Grim R.H. et al. For the MRFIT Research Group. Long-term eff ects of chlorthalidone vs hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor interventional trial // Hypertension. 2011. Vol. 57. P. 689–694.
51. Ernst ME, Neaton JD, Grimm RH Jr et al. Multiple Risk Factor Intervention Trial Research Group. Long-term eff ects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension 2011; 58 (6): 1001–7.
52. Ferrario C.M., Trask A.J., Jessup J.A. Advances in biochemical and functional roles of angiotensin–converting enzyme 2 and angiotensin–(l–7) in regulation of cardiovascular function // Am J Physiol Heart Circ Physiol. 2005. Vol. 289. Р. 2281–2290.
53. Finnerty FA. A double-blind study of chlorthalidone and hydrochlorothiazide in an outpatient population of moderate hypertensive's. Angiology 1976; 27: 738–44.
54. Fisher N.D. Hollenberg N.K. Renin inhibition: what are the therapeutic opportunities? // J. Am. Soc. Nephrol. – 2005. – Vol. 16. – P. 592-599.
55. Five-year fi ndings of the hypertension detection and follow-up program. I. reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979; 242 (23): 2562–71.
56. French C, Tarikuz Zaman AKM, Sobel BE. Th e angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011; 58: 143–8.
57. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, BothaJ, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A,Maggioni AP, ASTRONAUT Investigators and Coordinators. Eff ect of aliskiren on post discharge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013;309:1125–1135.
58. Gitt АК, Baumgart Р, Mahfoud F et al., for the EARLY Registry Group EARLY Treatment with azilsartan compared to ACEinhibitors in antihypertensive therapy – rationale and design of the EARLY hypertension registry. BMC Cardiovasc Dis 2013; 13 (46): 2–8.
59. Grinstead W.C., Young J.B. Th e myocardial renin-angiotensin system: existence, importance and clinical implications. Am Heart J 1992; 123: 1039–45.
60. Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) October 2014
61. Guideline on the Non-Clinical Documentation for Mixed Marketing Authorization Applications (CPMP/SWP/799/95).
62. Guidelines for registration of fi xed-dose combination medicinal products World Health Organization WHO Technical Report Series, No. 929, 2005
63. Handley Alison, Lloyd Eric, Roberts Andrew, Barger Bruce. Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. Clin Exp Hypertens, 2016; 38(2): 180–188.
64. Hao Jing, Rodriguez-Monguio Rosa, Seoane-Vazquez3 Enrique. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals PLOS ONE | October 15, 2015
65. Hatanaka Masaki, Kaimori1 Jun-Ya, Yamamoto Satoko, Matsui Isao,Hamano Takayuki, Takabatake Yoshitsugu, Ecelbarger Carolyn M., Takahara Shiro, Isaka Yoshitaka, RakugiHiromi. Azilsartan Improves Salt Sensitivity by vascular infl ammation and by increasing the phosphorylation ratio Ser1177/Th r497 of endothelial nitric oxide synthase in diabetic mice. Cardiovascular Diabetology 2014, http://www.cardiab.com/content/13/1/30
66. Hernandez Prada J.A., Ferreira A.J., Katovich M.J., Shenoy V., Qi Y., Santos R.A., Castellano R.K., Lampkins A.J., Gubala V., Ostrov D.A., Raizada M.K. Structure–based identifi cation of small–molecule angiotensin–converting enzyme 2 activators as novel antihypertensive agents // Hypertension. 2008. Vol. 51. Р. 1312–1317.
67. Hornig B., Kochler C., Drexler H Role of bradikinine in mediating vascular eff ects of angiotensin-converting enzyme inhibitors in humans// Circulation. – 1997. - Vol. 95. – P. 1115-1118.
68. http://healthdnepr.kiev.ua/
69. Hypertension: Evidence Update March 2013 A summary of selected new evidence relevant to NICE clinical guideline 127 'Clinical management of primary hypertension in adults' (2011) https://www.nice.org.uk/guidance/cg127/evidence/evidence-update-pdf-248584429.
70. Iwai M, Chen R, Imura Y, Horiuchi M. TAK0536, new AT1 receptor blocker, improves glucose intolerance and adipocyte diff erentiation. Am J Hypertens 2007; 20 (5): 579–86.
71. James PA, Oparil S, Carter BL et al. 2014. Evidence-Based Guidelines for the Management of High Blood Pressure in Adulds. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. doi: 10.1001/jama.2013.284427. Published online Dec 18, 2013.
72. Kajiya T, Ho C, Wang J et al. Molecular and cellular eff ects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011; 29: 2476–83.
73. Kipnes Mark S., Handley Alison, Lloyd Eric, Barger Bruce, Roberts Andrew. Safety, Tolerability, and Effi cacy of Azilsartan Medoxomil With or Without Chlorthalidone During and Aft er 8 Months of Treatment for Hypertension Th e Journal of Clinical Hypertension Vol 17 | No 3 | March 2015: 182-92.
74. Kurtz TW. Chlorthalidone: don't call it "thiazide-like" anymore. Hypertension. 2010; 56: 335–7.
75. Kusumoto K, Igata H, Ojima M et al. Antihypertensive, insulin-sensitizing and renoprotective eff ects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011; 669: 84–93.
76. Lastra Guido, Santos Fernando R., Hooshmand Payam, Hooshmand Paria, Mugerfeld Irina, Aroor Annayya R., DeMarco Vincent G., Sowers James R., Henriksen Erik J. Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle. Cardiorenal Med 2013;3:154–164
77. Lund-Johansenn P. Hemodynamic changes in long-term diuretic therapy of essential hypertension: a comparative study of chlorthalidone, polythiazide and hydrochlorothiazide // Acta Med. Scand. 1970; 187: 509-18.
78. Makani H, Bangalore S, Supariwala A et al. Antihypertensive effi cacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. Eur Heart J 2014; 35: 1732–42.
79. Mallion J., Baguet J., Siche J. et al. Cardiac and vascular remodeling: eff ect of antihypertensive drags// J. Hum. Hypertens. - 1999. - vol. 13 (Suppl. 1), S35-S42.
80. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
81. Mancia G., Zanchetti A., Agabiti-Rosei E. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy // Circulation. ‒ 1997. – Vol. 95. – Р.1464–1470.
82. Materson BJ, Oster JR, Michael UF et al. Dose response to chlorthalidone in patients with mild hypertension, effi cacy of a lower dose. Clin Pharmacol Th er 1978; 24: 192–8.
83. Matsumoto Sachiko, Shimabukuro Michio, Fukuda Daiju, Soeki Takeshi, Yamakawa Ken, Masuzaki Hiroaki, Sata Masataka. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular infl ammation and by increasing the phosphorylation ratio Ser1177/Th r497 of endothelial nitric oxide synthase in diabetic mice. Cardiovasc. Diab., 2014.
84. Mc Innes G. Angiotensin II receptor antagonists. London, 1998.
85. Menard J., Chatellier G. and Azizi M. Do we need angiotensin II antagonist to treat hypertensive patients . J. Hum. Hypertension, 1997, 11, 1-7.
86. Modulating the Proximal Tubular Na+-H+Exchanger-3 in Mice. PLOS ONE | DOI:10.1371/journal.pone.0147786 January 25, 2016
87. Neaton J.D., Grimm R.H. Jr, Prineas R.J. et al. Treatment of mild hypertension study: Final results: Treatment of Mild Hypertension Study Research Group // JAMA. 1993. Vol. 270. P. 713–724.
88. Neutel Joel M. , Cushman William C.,| Lloyd Eric3, Barger Bruce, Handley Alison. Comparison of long-term safety of fi xeddose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. J Clin Hypertens. 2017;1–10.
89. New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products
90. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Th er 2011; 336: 801–8. Zaiken K, Cheng JW. Azilsartan medoxomil: a new Angiotensin receptor blocker. Clin Th er 2011; 33 (11): 1577–89.
91. Oparil S. Newly emerging pharmacologic diff erences in angiotensin II receptor blockers. Am. J. Hypertens., 2000, 13 (1), 18-24.
92. Perez Alfonso, Cao Charlie. Th e Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Signifi cant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure Th e Journal of Clinical Hypertension2016;00:1–10.
93. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Metaanalysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendrofl umethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59: 1104–9.
94. Pickkers P, Garcha RS, Schachter M, Smits P, Hughes AD. Inhibition of carbonic anhydrase accounts for the direct vascular eff ects of hydrochlorothiazide. Hypertension. 1999;33:1043–8.
95. Pierini D. et al. Azilsartan medoxomil/chlorthalidone: a new fi xed-dose combination antihypertensive. Ann Pharmacother 2013; 47:694-703.
96. Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction aft er myocardial infarction // N. Engl. J. Med. – 2003. – Vol. 348. – P. 1309–1321.
97. Pitt B., Zannad F., Remme W.J. et al. Th e eff ect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators // N. Engl. J. Med. – 1999. – Vol. 341. – P. 709–717.
98. Potthoff S, Gitt A, Braumgart P et al. Blood pressure reduction by monotherapy with azilsartan as compared to ace inhibitors in clinical practice in GERMANY. Results of the EARLY REGISTRY. J Hypertens 2014; 32: e370-1.
99. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110: 1507–12.
100. Preston Richard A.,• Karim Aziz, Dudkowski Carolin, Zhao Zhen, Garg Dyal, Lenz Oliver, Domenic A. Sica. Single-Center Evaluation of the Single-Dose Pharmacokinetics of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Renal Impairment. Clin Pharmacokinet (2013) 52:347–358
101. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the effi cacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35: 552–8.
102. RALES-004 Study Group. New Eng J Med, 1999; 353: 754-61
103. Ramesh R Dargad, Jai D Parekh, Rohit R Dargad, Shweta Kukrety. Azilsartan: Novel Angiotensin Receptor Blocker Journal of Th e Association of Physicians of India Vol. 64 March 2016р96-98
104. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document/ G. Manciaa, S. Laurentb, E. Agabiti-Roseic et al./ Journal of Hypertension. - 2009. - Vol, 27:000–000.
105. Riess W., Dubach U.C., Burckhardt D., Th eobald W., Vuillard P., Zimmerli M. Pharmacokinetic studies with chlorthalidone (Hygroton) in man // Eur. J. Clin. Pharmacol. 1977; 12: 375-82.
106. Rouch G.C., Halford T.R., Guddati A.K. Chlortalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network mataanalyses // hypertension. –n2012. – Vol. 59. – p. 1110-1117.
107. Roush GC, Buddharaju V, Ernst ME. Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives? Curr Opin Cardiol 2013; 28 (4): 426–32.
108. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA.Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic eff ects. Hypertension. 2015. Vol65(%), 1041-6
109. Rousseau M.F., Konstam M.A., Benedict C.R. et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and eff ects of ibopamine therapy during long-term therapy with angiotensinconverting enzyme inhibitor. Am J Cardiol 1994; 73: 488–93.
110. Savage PJ, Pressel SL, Curb JD et al. Infl uence of long term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: Th e Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998; 158: 741–51.
111. Shawna D., Nesbitt M., Stevo J. Prehypertension: a possible target for antihypertensive medication. Current Hypertension reports, 2000, 2 (4), 357-361.
112. Sica D et al. Blood pressure-lowering effi cacy of the fi xed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J. Clin. Hypertens 2012;14:284-92.
113. Sica D, Bakris GL, White WB et al. New angiotensin II receptor blocker asilsartan medoxomil coadministered with chlorthalidones provides potential blood pressure reduction in stage 2 hypertension. Presented at: 25th AO Annual Scientifi c meeting; NY 1-4, 2010; New York, NY Poster PO-238.
114. Sica D, White W, Weber M et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens (Greenwich) 2011; 13: 467–72.
115. Systolic Hypertension in the Elderly Program Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program // JAMA. 1991. Vol. 265. P. 3255–3264.
116. Takagi Hisato, Mizuno Yusuke, Niwa Masao, Goto Shin-nosuke, UmemotoTakuya. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Umemoto Hypertension Research (2014) 37, 432–437.
117. Temperini C, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: sulfonamide diuretics revisited—old leads for new applications? Org Biomol Chem. 2008;6:2499–506.
118. The ALLHAT offi cers and coordinators for the ALLHAT collaborative research group. Major outcome in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) // JAMA. 2002. Vol. 288. P. 2981–2997.
119. The ALLHAT Offi cers and Coordinators for the ALLHAT Collaborative Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlortalidone // JAMA. 2000. Vol. 283. P. 1967–1975.
120. Trimmermans P., Wong P., Chui A. et al. Angiotensin II receptor and angiotensin II receptor antagonists// Pharmacol. Rev. - 1993. - vol. 45. p. 205-251.
121. Tsai Max C., WuJingtao, Kupfer Stuart, Vakilynejad Majid.Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 HypertensionTh e Journal of Clinical Pharmacology 2016, 00(0) 1–11
122. Ukimura Akira, Matsuda Hirohisa, Yamauchi Yoko, Yamamoto Kazuhisa, Hirai Kei, Ueno Nobuyuki 2, Yasuda Hideaki, Ono Shuta. Azilsartan is More Eff ective as Compared to Olmesartan in Hemodialysis Patients with Uncontrolled Hypertension J Nephrol Th er 2015, 5:1
123. Urata H., Healy B.H., Stewart R. et al. Angiotensin II forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883–90.
124. Wachtell K., Okin P.M., Olsen M.H. et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death; the LIFE STUDY// Circulation. – 2007, - Vol.. 145 (116). – P. 700-705.
125. Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participant from 42 trials / Am. J. Med. — 2009. — Vol. 122. — P. 290-300.
126. Wan Y., Wallinder C., Plouff e B., Beaudry H., Mahalingam A.K., Wu X., Johansson B., Holm M., Botoros M., Karlen A., Pettersson A., Nyberg F., Fandriks L., Gallo–Payet N., Hallberg A., Alterman M. Design, synthesis, and biological evaluation of the fi rst selective no peptide AT2 receptor agonist // J Med Chem. 2004. Vol. 47. Р.5995–6008.
127. Weber K.T., Barilla C.G. Pathological hypertrophy and cardiac interstitial: fi brosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849–65.
128. Weber K.T., Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71: 3А-111А.
129. Weber MA, Schiff rin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15.
130. Weber MA, White WB, Sica D, et al. Antihypertensive effi cacy of the new angiotensin receptor blocker azilsartan medoxomil in combination with amlodipine. Presented at: 25th ASH Annual Scientifi c Meeting; May 1-4, 2010. New York, NY. Poster PO-241
131. Weir M.R. Microalbuminuria and cardiovascular disease// Clin. J. Am. Col. Nephrol. – 2007. – Vol. 2. – P.581-590.
132. Whelton P.K., Barzilay J., Cushman W.C. et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Arch. Intern. Med. 2005; 165: 1401-9.
133. White W. B., Cuadra R.H., Lloyd E., Bakris G.L., Kupfer S. Eff ects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes Journal of Hypertension 2016, 34:788–797
134. White WB, Weber MA, Sica D et al. Eff ects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413–20.
135. White WB, Weber MA, Sica D et al. Th e eff ects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in diabetic and pre-diabetic patients. Presented at: 22nd Scientifi c Meeting of the European Society of Hypertension. April 26–29, 2012. London, United Kingdom. Poster.
136. Willenheimer R, Dahlof B, Rydberg E, Erhardt L. AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions// Eur. Heart J. -1999. - vol. 20 (14). – p. 997-1008.
137. Williams B. et al.; Newcastle Guideline Development and Research Unit // http://www.nice.org.uk/guidance/CG127
138. Wilson IM, Freis ED. Relationship between plasma and extracellular fl uid volume depletion and the antihypertensive eff ect of chlorothiazide. Circulation. 1959;20:1028–36.
139. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension 2010; 56 (3): 463–70.
140. Wright J.T. Jr, Harris-Haywood S., Pressel S. et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Arch. Intern. Med. 2008; 168: 207-17.
141. Wright J.T. Jr, Probstfi eld J.L., Cushman W.C. et al. ALLHAT fi ndings revisited in the context of subsequent analyses, other trials, and meta-analyses // Arch. Intern. Med. 2009; 169: 832-42.
142. Xiaodan Zhang, Qingyu Zhao. Association of Th iazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials Th e Journal of Clinical Hypertension Vol 18 | No 4 | April 2016.
143. Ye Y, Keyes KT, Zhang CF et al. Additive eff ect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Th er 2010; 24: 107–20.
144. Zaiken K, Cheng JW. Azilsartan medoxomil: a new Angiotensin receptor blocker. Clin. ther. 2011;339110:1577-87.
145. Zannad F, McMurray JJV,Krum H, VanVeldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B.Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
146. Zhao M, Li Y, Wang J et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab 2011; 13 (12):1123–9.